Voyager Therapeutics Inc
Company Profile
Business description
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
Contact
75 Hayden Avenue
LexingtonMA02421
USAT: +1 857 259-5340
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
172
Stocks News & Analysis
stocks
Undervalued ASX share with pathway to positive cash flow
stocks
Taiwan Semiconductor earnings: Buoyant guidance backed by voracious AI demand
stocks
Ahead of earnings, is Netflix a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,226.70 | 45.90 | 0.50% |
| CAC 40 | 8,258.94 | 54.18 | -0.65% |
| DAX 40 | 25,297.13 | 55.26 | -0.22% |
| Dow JONES (US) | 49,415.49 | 26.95 | -0.05% |
| FTSE 100 | 10,235.29 | 3.65 | -0.04% |
| HKSE | 26,844.96 | 78.66 | -0.29% |
| NASDAQ | 23,548.40 | 18.38 | 0.08% |
| Nikkei 225 | 53,936.17 | 174.33 | -0.32% |
| NZX 50 Index | 13,718.10 | 58.31 | 0.43% |
| S&P 500 | 6,950.17 | 5.70 | 0.08% |
| S&P/ASX 200 | 8,903.90 | 48.10 | 0.54% |
| SSE Composite Index | 4,101.91 | 10.69 | -0.26% |